Manila Times Business
Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab for First-Line Treatment of PD-L1-Positive NSCLC Published in The Lancet
CHENGDU, China, May 31, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company", 6990.HK) announced today that the results of the Phase III clinical study OptiTROP-Lung05, evaluating the company's trophoblast cell-surface antigen 2 (TROP2)-directed antibody drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT, also known as SKB264/MK-2870)(佳泰莱®) in combination with pembrolizumab (KEYTRUDA®[1], MSD's anti-programmed cell death protein 1 (PD-1) antibody) as first-lin
This is an excerpt. Read the full article at the original source:
Source: manilatimes.net
Read Full Article on manilatimes.net →More from Manila Times Business
Solana Unchained Outlines Fixed-Supply Utility Architecture and AI Tool Hub Ahead of Late May Public Allocation Launch
3h ago
IBF champ Jerwin Ancajas’ nephew snares gold in Palaro boxing
4h ago
Espenilla, Cadag deliver breakthrough medals at Asian U20 Championships
4h ago
NCR extends Palarong Pambansa dynasty with 19th straight overall title
4h ago